Trial Profile

Efficacy of nintedanib antifibrotic therapy for severe COVID-19 pneumonia: A historical controlled single-arm trial.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Corticosteroids; Favipiravir; Heparin
Indications Adult respiratory distress syndrome; COVID-19 pneumonia; Pulmonary fibrosis
Focus Therapeutic Use

Most Recent Events

30 Aug 2021 New trial record
01 Jul 2021 Primary endpoint has not been met. (28-day mortality after the initiation of mechanical ventilation), as per Results published in the International Journal of Infectious Diseases
01 Jul 2021 Results published in the International Journal of Infectious Diseases

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com